نتایج جستجو برای: ژن pik3ca

تعداد نتایج: 18195  

2013
Fiona L. Day Robert N. Jorissen Lara Lipton Dmitri Mouradov Anuratha Sakthianandeswaren Michael Christie Shan Li Cary Tsui Jeannie Tie Jayesh Desai Zheng-Zhou Xu Peter Molloy Vicki Whitehall Barbara A. Leggett Ian T. Jones Stephen McLaughlin Robyn L. Ward Nicholas J. Hawkins Andrew R. Ruszkiewicz James Moore Dana Busam Qi Zhao Robert L. Strausberg Peter Gibbs Oliver M. Sieber

Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of response to mitogen-activated protein/extracellular signal–regulated kinase inhibitors and anti-EGF receptor antibody therapy. Relationships between phosphoinositide 3-kinase (PI3K) pathway mutation, clinicopathologic characteristics, molecular features, and prognosis remain controversial. Experimenta...

2018
Odekunle Florence Femi

Introduction A number of studies indicated racial differences in cervical cancer outcomes and several factors are associated with it such as stage, comorbidities, treatment pattern, and socioeconomic status. However, the associations of tumor genomic patterns such as phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene mutations and amplifications with cervical cancer racial disp...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2012
C Mao Z Y Yang X F Hu Q Chen J L Tang

BACKGROUND We conducted a systematic review and meta-analysis to dissect the association between PIK3CA mutations and resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) according to PIK3CA exon of mutations in metastatic colorectal cancer (mCRC). METHODS We systematically identified studies exploring the association between PIK3CA mutations and clinical o...

2016
Baltruškevičienė Edita Mickys Ugnius Žvirblis Tadas Stulpinas Rokas Pipirienė Želvienė Teresė Aleknavičius Eduardas

Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. The aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal canc...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2007
Christian Hafner Elena López-Knowles Nuno M Luis Agustí Toll Eulàlia Baselga Alex Fernández-Casado Silvia Hernández Adriana Ribé Thomas Mentzel Robert Stoehr Ferdinand Hofstaedter Michael Landthaler Thomas Vogt Ramòn M Pujol Arndt Hartmann Francisco X Real

Activating mutations of the p110 alpha subunit of PI3K (PIK3CA) oncogene have been identified in a broad spectrum of malignant tumors. However, their role in benign or preneoplastic conditions is unknown. Activating FGF receptor 3 (FGFR3) mutations are common in benign skin lesions, either as embryonic mutations in epidermal nevi (EN) or as somatic mutations in seborrheic keratoses (SK). FGFR3 ...

2012
Ignacio Garrido-Laguna David S. Hong Filip Janku Ly M. Nguyen Gerald S. Falchook Siqing Fu Jenifer J. Wheler Rajyalakshmi Luthra Aung Naing Xuemei Wang Razelle Kurzrock

PURPOSE To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents. PATIENTS AND METHODS We analyzed characteristics of 238 patients with mCRC referred to the phase 1 trials unit at MD Anderson Cancer Center. KRAS, PIK3CA and BRAF status were tested using PCR-based DNA sequen...

Journal: :Molecular cancer therapeutics 2012
Craig P Carden Adam Stewart Parames Thavasu Emma Kipps Lorna Pope Mateus Crespo Susana Miranda Gerhardt Attard Michelle D Garrett Paul A Clarke Paul Workman Johann S de Bono Martin Gore Stan B Kaye Udai Banerji

Evidence that the phosphoinositide 3-kinase (PI3K) pathway is deregulated in ovarian cancer is largely based on the analysis of surgical specimens sampled at diagnosis and may not reflect the biology of advanced ovarian cancer. We aimed to investigate PI3K signaling in cancer cells isolated from patients with advanced ovarian cancer. Ascites samples were analyzed from 88 patients, of whom 61 re...

Journal: :Folia neuropathologica 2010
Ewa Izycka-Swieszewska Magdalena Brzeskwiniewicz Agnieszka Wozniak Elżbieta Drozynska Wiesława Grajkowska Danuta Perek Anna Balcerska Teresa Klepacka Janusz Limon

PI3K/AKT/mTOR pathway signalling is often upregulated in cancer, usually by the constitutional activation of growth factor receptors, amplification or mutation of PIK3CA and loss of tumour suppressor PTEN function. The way of PI3K/AKT/mTOR pathway activation in neuroblastoma (NB) is not well established. The study was performed on paraffin-embedded tissue sections from 106 patients with NB. The...

Journal: :Oncology reports 2009
Guadalupe Sequeiros-Santiago Dario García-Carracedo Manuel F Fresno Carlos Suarez Juan P Rodrigo M Victoria Gonzalez

The aim of the present study was the search of molecular alterations (oncogene amplification or protein overexpression) that could have an impact on the outcome of ACC patients. For this purpose, paraffin-embedded tissue samples of primary ACC of 24 patients were collected. Oncogenic amplification status of six targets previously described to be involved in human carcinogenesis (ERBB1, KIT, PIK...

2017
Chung-Ho E. Lau Gregory D. Tredwell James K. Ellis Eric W.-F. Lam Hector C. Keun

Somatic mutations in PIK3CA are frequently found in a number of human cancers, including breast cancer, altering cellular physiology and tumour sensitivity to chemotherapy. This renders PIK3CA an attractive molecular target for early detection and personalised therapy. Using 1H Nuclear Magnetic Resonance spectroscopy (NMR) and Gas Chromatography - Mass Spectrometery (GC-MS) together with 13C st...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید